198 related articles for article (PubMed ID: 36459415)
1. Potent Ruthenium-Ferrocene Bimetallic Antitumor Antiangiogenic Agent That Circumvents Platinum Resistance: From Synthesis and Mechanistic Studies to
M M; Gadre S; Chhatar S; Chakraborty G; Ahmed N; Patra C; Patra M
J Med Chem; 2022 Dec; 65(24):16353-16371. PubMed ID: 36459415
[TBL] [Abstract][Full Text] [Related]
2. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the Microtubule Network and Inhibition of VEGFR2 Phosphorylation by Cytotoxic
Acharya S; Maji M; Chakraborty MP; Bhattacharya I; Das R; Gupta A; Mukherjee A
Inorg Chem; 2021 Mar; 60(5):3418-3430. PubMed ID: 33554592
[TBL] [Abstract][Full Text] [Related]
4. Ru
Lenis-Rojas OA; Robalo MP; Tomaz AI; Carvalho A; Fernandes AR; Marques F; Folgueira M; Yáñez J; Vázquez-García D; López Torres M; Fernández A; Fernández JJ
Inorg Chem; 2018 Nov; 57(21):13150-13166. PubMed ID: 30339386
[TBL] [Abstract][Full Text] [Related]
5. Activation by Oxidation: Ferrocene-Functionalized Ru(II)-Arene Complexes with Anticancer, Antibacterial, and Antioxidant Properties.
Mu C; Prosser KE; Harrypersad S; MacNeil GA; Panchmatia R; Thompson JR; Sinha S; Warren JJ; Walsby CJ
Inorg Chem; 2018 Dec; 57(24):15247-15261. PubMed ID: 30495936
[TBL] [Abstract][Full Text] [Related]
6. Necrosis-Inducing High-Valent Oxo-Rhenium(V) Complexes with Potent Antitumor Activity: Synthesis, Aquation Chemistry, Cisplatin Cross-Resistance Profile, and Mechanism of Action.
Das S; Joshi P; Patra M
Inorg Chem; 2023 Dec; 62(48):19720-19733. PubMed ID: 37974075
[TBL] [Abstract][Full Text] [Related]
7. A Cytostatic Ruthenium(II)-Platinum(II) Bis(terpyridyl) Anticancer Complex That Blocks Entry into S Phase by Up-regulating p27(KIP1).
Ramu V; Gill MR; Jarman PJ; Turton D; Thomas JA; Das A; Smythe C
Chemistry; 2015 Jun; 21(25):9185-97. PubMed ID: 25950156
[TBL] [Abstract][Full Text] [Related]
8. Modulating the Anticancer Activity of Ruthenium(II)-Arene Complexes.
Clavel CM; Păunescu E; Nowak-Sliwinska P; Griffioen AW; Scopelliti R; Dyson PJ
J Med Chem; 2015 Apr; 58(8):3356-65. PubMed ID: 25812075
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos.
Golbaghi G; Pitard I; Lucas M; Haghdoost MM; de Los Santos YL; Doucet N; Patten SA; Sanderson JT; Castonguay A
Eur J Med Chem; 2020 Feb; 188():112030. PubMed ID: 31945643
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activity and mechanism of bis-pyrimidine based dimetallic Ru(II)(η
Bhatti MZ; Ali A; Duong HQ; Chen J; Rahman FU
J Inorg Biochem; 2019 May; 194():52-64. PubMed ID: 30831390
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy.
Zhang X; Liu D; Lv F; Yu B; Shen Y; Cong H
Colloids Surf B Biointerfaces; 2019 Oct; 182():110373. PubMed ID: 31376689
[TBL] [Abstract][Full Text] [Related]
12. A Rationally Designed Bimetallic Platinum (II)-Ferrocene Antitumor Agent Induces Non-Apoptotic Cell Death and Exerts in Vivo Efficacy.
Gadre S; Manikandan M; Duari P; Chhatar S; Sharma A; Khatri S; Kode J; Barkume M; Kasinathan NK; Nagare M; Patkar M; Ingle A; Kumar M; Kolthur-Seetharam U; Patra M
Chemistry; 2022 Aug; 28(46):e202201259. PubMed ID: 35638709
[TBL] [Abstract][Full Text] [Related]
13. Metal complexes as DNA intercalators.
Liu HK; Sadler PJ
Acc Chem Res; 2011 May; 44(5):349-59. PubMed ID: 21446672
[TBL] [Abstract][Full Text] [Related]
14. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
Ma L; Ma R; Wang Z; Yiu SM; Zhu G
Chem Commun (Camb); 2016 Sep; 52(71):10735-8. PubMed ID: 27506281
[TBL] [Abstract][Full Text] [Related]
15. Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study.
Yellol J; Pérez SA; Buceta A; Yellol G; Donaire A; Szumlas P; Bednarski PJ; Makhloufi G; Janiak C; Espinosa A; Ruiz J
J Med Chem; 2015 Sep; 58(18):7310-27. PubMed ID: 26313136
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of ferrocenyl-ethynyl phosphine metal complexes of gold and platinum.
Fourie E; Erasmus E; Swarts JC; Jakob A; Lang H; Joone GK; VAN Rensburg CE
Anticancer Res; 2011 Mar; 31(3):825-9. PubMed ID: 21498702
[TBL] [Abstract][Full Text] [Related]
17. Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway.
Chen L; Wang J; Cai X; Chen S; Zhang J; Li B; Chen W; Guo X; Luo H; Chen J
Bioorg Chem; 2022 Feb; 119():105516. PubMed ID: 34856444
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo accumulation of the anticancer Ru complexes [Ru
Riisom M; Morrow SJ; Herbert CD; Tremlett WDJ; Astin JW; Jamieson SMF; Hartinger CG
J Biol Inorg Chem; 2023 Dec; 28(8):767-775. PubMed ID: 37962611
[TBL] [Abstract][Full Text] [Related]
19. A Multi-action and Multi-target Ru
Karges J; Yempala T; Tharaud M; Gibson D; Gasser G
Angew Chem Int Ed Engl; 2020 Apr; 59(18):7069-7075. PubMed ID: 32017379
[TBL] [Abstract][Full Text] [Related]
20. A Macrocyclic Ruthenium(III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo.
Kwong WL; Lam KY; Lok CN; Lai YT; Lee PY; Che CM
Angew Chem Int Ed Engl; 2016 Oct; 55(43):13524-13528. PubMed ID: 27717148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
